日本糖尿病市场报告：2026-2034年

2025年，日本糖尿病市场规模达58亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到76亿美元，2026年至2034年的复合年增长率为2.95%。推动该市场成长要素包括老年人口增加、糖尿病盛行率上升、政府支持措施带来的医疗保健支出增加以及治疗方法的进步。

日本糖尿病市场分析：

• 市场主要驱动因素：生活方式的改变和人口老化导致日本糖尿病盛行率不断上升，这是成长要素。此外，近期调查显示，糖尿病患者人数持续成长，进一步刺激了日本糖尿病市场的需求。政府也已拨款并实施多项卫生措施，以加强糖尿病的治疗和管理。这些措施包括糖尿病治疗补助和旨在促进市场扩张的公共卫生措施。
• 市场主要趋势：胰岛素帮浦和持续血糖监测仪（CGM）等先进的糖尿病照护技术正日益普及。此外，受遗传因素研究进展以及患者对更有效率、更专业的糖尿病管理方案的个人化需求的推动，个人化治疗方案和定製药物的使用也成为一种趋势。
• 竞争格局：日本糖尿病市场由大型国际製药公司和医疗设备製造商主导。这些公司凭藉丰富的产品线和最尖端科技保持竞争力。此外，日本公司也提供创新产品和客製化解决方案，以满足日本患者的需求。
• 挑战与机会：市场挑战包括对新型糖尿病治疗方法的严格监管和漫长的核准流程。另一方面，人口老化为开发针对该族群的糖尿病治疗和管理方案提供了巨大机会。此外，远端医疗和行动医疗应用等数位健康技术的进步，也为更深入与患者互动和改善糖尿病管理创造了新的可能性。

日本糖尿病市场的发展趋势：

糖尿病盛行率不断上升

日本糖尿病市场的成长主要受糖尿病盛行率上升的驱动。根据国际糖尿病联盟（IDF）的数据，截至2021年，日本成年人口为93,187,400，糖尿病盛行率为11.8%，即11,004,999人。因此，由于对包括先进药物和监测设备在内的综合糖尿病护理解决方案的需求不断增长，市场正在扩张。此外，随着患者人数的增加，製药公司和医疗保健专业人员被迫研发并提供各种治疗方案，以满足患者的多样化需求。同时，随着糖尿病患者人数的增加，旨在改善患者治疗效果和生活品质的糖尿病专科医疗保健服务也不断扩展。因此，这一趋势正在推动抗糖尿病药物的销售，并刺激创新血糖监测技术的市场发展，这些技术有望提供更精准、更便捷的监测方案，从而为日本糖尿病市场带来光明的前景。

人口老化的过程

根据内务部的报告，截至2023年9月15日，日本65岁以上人口已达3,622.7万人。此外，老年人口占总人口的比例上升了0.1个百分点，达到29.1%，创历史新高。由于老年人更容易患上第2型糖尿病，因此对专业的糖尿病管理项目和产品的需求日益增长。受人口结构变化的影响，医疗机构和临床医生正致力于老年糖尿病的治疗，推动药物治疗、营养指导和病患教育等方面的进步，使其更符合老年人的需求。人口老化也影响现有高需求服务和产品的供应。这些服务和产品易于使用且侵入性小，非常适合老年患者，因此也导致了糖尿病治疗需求的增加。

政府支持措施和医疗成本

日本政府积极加大医疗保健支出力度，包括为治疗糖尿病等慢性疾病拨出大量预算，正推动日本糖尿病市场的发展。根据Frontiers统计，2020年日本国民医疗保健支出飙升至43兆日圆（约3,040亿美元），几乎是1990年的两倍。这相当于其占国内生产总值的比重从4.6%上升至8.0%。此外，政府正致力于确保糖尿病照护资金充足，改善治疗可近性，并控制治疗费用。这些项目涵盖从先进治疗方法方案到一级预防的各个方面，正在夯实糖尿病护理的基础。同时，众多政府主导的、以筛检和公共卫生宣传活动为重点的倡议，旨在降低糖尿病盛行率并改善社区层面的主导，这些倡议也促进了市场成长。因此，这些全面的健康政策透过提高意识提升、促进早期发现以及将先进的糖尿病护理纳入公共卫生体系，正在推动日本糖尿病市场的成长。

目录

第一章：序言

第二章：调查方法

• 调查目的
• 相关利益者
• 数据来源
  • 主要讯息
  • 次要讯息
• 市场估值
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章执行摘要

第四章：引言

第五章：糖尿病概述

• 什么是糖尿病？
• 糖尿病的诊断和治疗
  • 诊断
  • 治疗
• 糖尿病併发症

第六章：日本糖尿病流行病学

• 糖尿病患者人数及盛行率
• 人口和盛行率：按糖尿病类型（1 型和 2 型）划分
• 人口和盛行率：按地区划分
• 人口和盛行率：按性别划分
• 人口和盛行率：按年龄组别划分

第七章：日本糖尿病市场

• 市场概览
• 市场表现
• 新冠疫情的影响
• 市场预测
• SWOT分析
• 价值链分析
• 波特五力分析
• 市场区隔：按细分市场

第八章 竞争情势

• 市场结构
• 主要企业简介

The Japan diabetes market size reached USD 5.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 7.6 Billion by 2034, exhibiting a growth rate (CAGR) of 2.95 % during 2026-2034. The market is primarily driven by the growing geriatric population, increased prevalence of diabetes, enhanced healthcare spending with supportive government initiatives, and technological advancements in treatment options.

JAPAN DIABETES MARKET ANALYSIS:

• Major Market Drivers: The rising prevalence of diabetes in Japan due to the changing lifestyles and an aging population represents a major growth-inducing factor. In addition, recent research indicates that the diabetic patient population is still growing, which is increasing the Japan diabetes market demand. Besides, the government has funded and executed several health initiatives to enhance the treatment and management of diabetes. These include diabetes treatment subsidies and public health initiatives that encourage market expansion.
• Key Market Trends: Advanced diabetes care technology like insulin pumps and continuous glucose monitors (CGMs) are becoming more popular. Moreover, the market is witnessing a trend toward individualized treatment plans and customized medicines, which is driven by greater research into genetic variables and unique patient demands to deliver more efficient and specialized diabetes management solutions.
• Competitive Landscape: The Japanese diabetes market is dominated by giant international pharmaceutical and medical device businesses, as their wide range of products and cutting-edge technology help them to stay competitive. Additionally, Japanese companies are offering innovations and customized solutions specific to the requirements of Japanese patients.
• Challenges and Opportunities: Challenges in the market include stringent regulatory regulations and protracted approval procedures for novel diabetic therapies. On the other hand, the growing geriatric population offers substantial opportunities for the development of diabetes treatment and management programs specifically designed for this demographic. Besides, the development of digital health technologies, such as telemedicine and mobile health apps, creates new possibilities for better patient engagement and diabetes management.

JAPAN DIABETES MARKET TRENDS :

Rising Diabetes Prevalence

The growth of the diabetes market in Japan is driven by the rising incidence of diabetes. According to the International Diabetes Federation (IDF) reports, with 93,187,400 individuals in the country as of 2021, the prevalence rate of diabetes is 11.8% or 11,004,999 cases among adults. As a result, the market is expanding due to the increasing need for complete diabetes care solutions, which include cutting-edge drugs and monitoring equipment. Moreover, pharmaceutical businesses and healthcare professionals are compelled by the increasing number of patients to create and offer a wide array of treatment alternatives that address the diverse demands of their patients. In addition, the rise in diabetes cases has increased diabetes-specific healthcare services that attempt to enhance patient outcomes and quality of life. Hence, this trend has propelled the sales of anti-diabetic medications and boosted the market for innovative glucose monitoring technologies that promise more accurate and user-friendly options, thus creating a positive Japan diabetes market outlook.

Growing Geriatric Population

As reported by the Ministry of Internal Affairs and Communications, Japan's elderly population, those aged 65 and above, reached 36,227 thousand as of September 15, 2023. Moreover, the proportion of seniors in the overall population increased by 0.1% points to 29.1%, the highest percentage ever recorded. Additionally, the elderly are more susceptible to type 2 diabetes , which escalates the need for specialized diabetes management programs and products. This change in the population motivates healthcare organizations and clinicians to concentrate on the treatment of geriatric diabetes, resulting in advancements in medication therapy, nutritional guidance, and patient education customized to the needs of the geriatric population. Besides, the aging population influences several services and products that are in demand, offer simple use and low invasiveness, which are ideal for senior patients, and increase the volume of diabetic treatments that are necessary.

Supportive Government Initiatives and Healthcare Spending

The diabetes market is driven by the government of Japan's aggressive approach to healthcare spending, which includes a sizeable budget for treating chronic illnesses like diabetes. According to Frontiers, in 2020, Japan's national medical spending skyrocketed to 43 Trillion yen (304 Billion USD), nearly doubling from past figures since 1990. This indicates an increase in the nation's gross domestic output from 4.6% to 8.0%. In addition, the government ensures that enough money is spent on diabetes care, which makes treatments more accessible and reasonably priced. The foundation of diabetes care is being improved due to these programs, which cover everything from sophisticated treatment choices to primary prevention. In addition, numerous government initiatives concentrated on screenings and public health campaigns to lower the prevalence of diabetes while improving its management at the community level are influencing the market growth. Hence, these comprehensive health policies support Japan diabetes market growth by increasing awareness and early detection while integrating advanced diabetes care into the public health system.

JAPAN DIABETES MARKET SEGMENTATION:

Breakup by Segment:

• Oral Antidiabetics
• Insulin

Insulin accounts for the majority of the market share

Insulin reflects a substantial portion of the market share due to the increasing prevalence of diabetes among the aging population and the rising adoption of insulin therapies for effective glucose management. Additionally, Japan's healthcare system, renowned for its efficiency, extensively supports diabetes care, enabling widespread access to insulin treatments. Moreover, the market benefits from advancements in insulin formulations and delivery systems, which enhance patient adherence and outcomes. Besides, the Japanese government's proactive health initiatives aim to improve diabetes awareness and screening, further driving the demand for insulin. Furthermore, this segment's growth is also fueled by collaborations between domestic pharmaceutical companies and global diabetes care leaders, aiming to innovate and expand the availability of cutting-edge insulin solutions tailored to the unique needs of Japanese patients. Hence key players are introducing advanced product variants to meet these needs. For instance, in March 2023, in Tokyo Japan, and Taipei, Taiwan, Health2Sync, announced the recent update of its Health2Sync App now including insulin data from the Mallya Cap, a connected device for insulin pens created by Biocorp and marketed in Japan by Novo Nordisk. This collaboration introduces the world's first integration of this type of data and is designed to aid patients undergoing insulin treatment by tracking various health metrics, such as insulin injection records. Due to these innovations, the Japan diabetes market forecast states that insulin segment will continue to dominate the market.

COMPETITIVE LANDSCAPE:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided.
• At present, key players in the market are actively enhancing growth through strategic collaborations, advanced research and development (R&D) initiatives, and educational programs to improve diabetes management. Additionally, companies like Novo Nordisk and Sanofi are investing heavily in the development of next-generation insulin therapies and glucose monitoring systems tailored to meet the specific needs of Japanese patients, thus accounting for the Japan diabetes market share. These firms collaborate closely with local healthcare providers to ensure broad distribution and integration of their products into daily medical practice. Furthermore, these market leaders support extensive patient education campaigns to increase awareness about diabetes symptoms, treatment options, and lifestyle adjustments necessary for effective disease management. These comprehensive strategies strengthen their market position and significantly contribute to improving patient outcomes in Japan. For instance, on 29 March 2023, Maryland, Astellas Pharma Inc. announced its partnership with Roche Diabetes Care Japan Co., Ltd. This partnership focuses on the development and commercialization of the globally recognized Accu-Chek Guide Me blood glucose monitoring system, noted for its high accuracy, in conjunction with BlueStar(R)*1. BlueStar, an FDA-approved digital health solution for managing diabetes, is developed by Welldoc, Inc. and is available in the U.S. and Canada. Astellas and Welldoc are collaboratively advancing BlueStar's development in Japan. Astellas plans to seek regulatory approval and reimbursement for this integrated medical product in the future.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the Japan diabetes market performed so far, and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan diabetes market?
• What is the breakup of the Japan diabetes market on the basis of segment?
• What are the various stages in the value chain of the Japan diabetes market?
• What are the key driving factors and challenges in the Japan diabetes market?
• What is the structure of the Japan diabetes market, and who are the key players?
• What is the degree of competition in the Japan diabetes market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Diabetes Disease Overview

• 5.1 What is Diabetes?
• 5.2 Diabetes Diagnosis and Treatment
  • 5.2.1 Diagnosis
  • 5.2.2 Treatment
• 5.3 Diabetes Complications

6 Japan Diabetes Epidemiology

• 6.1 Diabetes Population and Prevalence Rates
• 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
• 6.3 Population and Prevalence Rates by Region
• 6.4 Population and Prevalence Rates by Gender
• 6.5 Population and Prevalence Rates by Age Group

7 Japan Diabetes Market

• 7.1 Market Overview
• 7.2 Market Performance
• 7.3 Impact of COVID-19
• 7.4 Market Forecast
• 7.5 SWOT Analysis
  • 7.5.1 Overview
  • 7.5.2 Strengths
  • 7.5.3 Weaknesses
  • 7.5.4 Opportunities
  • 7.5.5 Threats
• 7.6 Value Chain Analysis
• 7.7 Porter's Five Forces Analysis
  • 7.7.1 Overview
  • 7.7.2 Bargaining Power of Buyers
  • 7.7.3 Bargaining Power of Suppliers
  • 7.7.4 Degree of Competition
  • 7.7.5 Threat of New Entrants
  • 7.7.6 Threat of Substitutes
• 7.8 Market Breakup by Segment
  • 7.8.1 Japan Oral Antidiabetics Market
    • 7.8.1.1 Historical Market Trends
    • 7.8.1.2 Market Breakup by Class
    • 7.8.1.3 Market Shares of Key Players
    • 7.8.1.4 Market Forecast
  • 7.8.2 Japan Insulin Market
    • 7.8.2.1 Historical Market Trends
    • 7.8.2.2 Market Breakup by Class
    • 7.8.2.3 Market Shares of Key Players
    • 7.8.2.4 Market Forecast

8 Competitive Landscape

• 8.1 Market Structure
• 8.2 Profiles of Key Players

List of Figures

• Figure 1: The Impact of Diabetes in the Human Body
• Figure 2: Diabetes Complications
• Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2025 & 2034
• Figure 4: Body Mass Index and Relative risk of Type-2 Diabetes
• Figure 5: Japan: Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 6: Japan: Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 7: Japan (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 8: Japan (Type1 & Type2): Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 9: Japan (Urban & Rural): Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 10: Japan (Urban & Rural): Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 11: Japan (Male & Female): Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 12: Japan (Male & Female): Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 13: Japan: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2020-2025
• Figure 14: Japan: Total Number of Diabetes Patients Forecast by Age Group (20-39), (40-59) & (60-79) (in 000), 2026-2034
• Figure 15: Japan: Diabetes Drug Industry Overview
• Figure 16: Japan: Diabetes Drug Market: Sales Value (in Billion USD), 2020-2025
• Figure 17: Japan: Diabetes Drug Market Forecast: Sales Value (in Billion USD), 2026-2034
• Figure 18: Japan: Diabetes Drug Market: SWOT Analysis
• Figure 19: Japan: Diabetes Drug Market: Value Chain Analysis
• Figure 20: Japan: Diabetes Drug Market: Porters Five Forces Analysis
• Figure 21: Japan: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2020-2025
• Figure 22: Japan: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2026-2034
• Figure 23: Japan: Oral Antidiabetics Market: Sales Value (in Million USD), 2020-2025
• Figure 24: Japan: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2020 & 2025
• Figure 25: Japan: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
• Figure 26: Japan: Oral Antidiabetics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 27: Japan: Insulin Market: Sales Value (in Million USD), 2020-2025
• Figure 28: Japan: Breakup of Insulin Market by Class (in %), 2025
• Figure 29: Japan: Insulin Market: Sales Share of Key Players (in %)
• Figure 30: Japan: Insulin Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

• Table 1: Diagnosis of Diabetes
• Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2025 and 2034
• Table 3: Japan: Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 4: Japan (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 5: Japan (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 6: Japan (Male & Female): Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 7: Japan: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79 - in Millions), 2020, 2025 & 2034
• Table 8: Japan: Diabetes Drug Market: Competitive Structure